FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy
Related Topics >> Wyeth | Pfizer | Patent | Mylan | Generic drugs | Effexor XR

Mylan, Wyeth ink Effexor agreements

Tools

Mylan Pharmaceuticals has entered into settlement and license agreements with Wyeth, now part of Pfizer, relating to venlafaxine HCl ER capsules in 37.5-, 75- and 150-mg strengths. The product is the generic version of Wyeth's Effexor XR capsules, a treatment for major depressive disorder. Mylan will be granted a non-exclusive license to the relevant patents that would permit it to launch the capsules in the U.S. on or after June 1, 2011--or earlier in limited circumstances. Additional details of the agreement remain confidential. Release

Twitter   Facebook   LinkedIn   StumbleUpon  
Get Your FREE FiercePharma Email Newsletter:
Be the first to comment
More stories about Pfizer   Patent   Mylan   Generic drugs   Effexor XR   Wyeth  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.